High-Grade Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

High-Grade Glioma Market Outlook

Thelansis’s “High-Grade Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential High-Grade Glioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

High-Grade Glioma Overview

High-grade gliomas (HGGs) encompass various types of malignant brain tumors, including anaplastic astrocytomas, anaplastic oligoastrocytomas, glioblastoma multiforme (GBM), gliosarcomas, and anaplastic oligodendrogliomas, falling under WHO grades III and IV. They can originate directly from glial cells or from low-grade gliomas that transform into higher-grade malignancies. Patients with HGGs often exhibit a range of symptoms, such as memory dysfunction due to the tumor's invasive nature beyond the enhancing tumor boundaries. These symptoms may or may not aid in pinpointing the tumor's location. Family members and patients frequently recall personality changes and memory loss when discussing the patient's medical history. Headaches and vomiting are typically linked to increased intracranial pressure, with the headache's location being nonspecific. Seizures can be an initial symptom or manifest after diagnosis or during treatment. Neurological deficits correlate with the tumor's location and associated vasogenic edema. High-grade gliomas in children and adolescents are uncommon but tend to display highly malignant behavior, characterized by rapid growth and the destruction of healthy brain tissue. They constitute approximately 15 to 20% of CNS tumors in this age group. These HGGs can be classified based on their location within the central nervous system (CNS), cell of origin, and degree of malignancy. The median survival for patients without any treatment is less than six months, and even with standard-of-care treatment, it extends to only 14.6 months.

• The incidence rate in Europe and North America is approximately 5 per 100,000 person-years. Of these cases, around 70% arenglioblastomas, isocitrate dehydrogenase (IDH)-wildtype or astrocytoma, IDH-mutant, grade 4. Roughly 15% are astrocytoma, IDH-mutant, grade 3, and about 10% are oligodendroglioma, IDH-mutant and 1p/19q deleted grade 3.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: